NCT01072162View on ClinicalTrials.gov

Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food Effect

PHASE1CompletedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

January 12, 2010

Primary Completion Date

April 7, 2010

Study Completion Date

April 7, 2010

Conditions

Purpura, Thrombocytopaenic, Idiopathic

Interventions

DRUG

Eltrombopag

25 mg tablet

DRUG

Eltrombopag

25 mg powder for oral suspension

Trial Locations (1)

14202

GSK Investigational Site, Buffalo

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01072162 - Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food Effect | Biotech Hunter | Biotech Hunter